
The Board of Directors and Executive Management have considered and approved the Annual Report for 2008 of Novozymes A/S.
The consolidated financial statements are presented in accordance with the International Financial Reporting Standards, as adopted by the EU, and the Parent Company financial statements are presented in accordance with the Danish Financial Statements Act. In addition, the Annual Report has been prepared in accordance with the additional Danish annual report requirements for listed companies.
In our opinion, the accounting policies used are appropriate, and the Group’s internal controls relevant to preparation and presentation of an annual report are adequate. The Annual Report therefore provides a true and fair view of the Group’s and the Parent Company’s assets, liabilities and financial position at December 31, 2008 and of the results of the Group’s and the Parent Company’s operations and consolidated cash flows for the financial year 2008.
We further consider that the Management’s review in the Annual Report gives a true and fair view of the development in the Group’s activities and business, the profit for the year, and the Group’s financial position as a whole, and a description of the most significant risks and uncertainties to which the Group is subject.
We recommend that the Annual Report be approved by the Annual Shareholders’ Meeting.
Bagsvaerd, January 22, 2009
Management: |
||||
Steen Riisgaard |
||||
Per Falholt |
Benny D. Loft |
Thomas Nagy |
Peder Holk Nielsen |
Thomas Videbæk |
Board of Directors: |
||||
|
Kurt Anker Nielsen |
Paul Petter Aas |
Arne Juul Hansen |
Jerker Hartwall |
|
Ulla Morin |
Walther Thygesen |
Mathias Uhlén |
|